News Release

Asieris Pharmaceuticals establish collabration with US Chinese Anti-cancer Association

US Chinese Anti-Cancer Association (USCACA) and Broad Sources/Jiangsu Yahong Pharmaceuticals (BSI/Yahong) announced today to enter into partnership to develop novel anti-cancer drugs, and particularly for treating prevalent cancer types in China. USCACA will provide supports to the clinical development of BSI/Yahong drug candidates through its clinical expert and trial network in the US and China. The goal of the partnership is to accelerate the development of innovative anti-cancer drugs by conducting early-stage clinical trials in patients with cancers prevalent in China. This partnership can also expedite the drugs’ availability to patients in China, and provide opportunities to bridge the gap of clinical studies between China and the US.

“The collaboration with USCACA perfectly fits our strategy to integrate China into our global development. By working with USCACA, we look forward to rapidly expanding our access to clinical oncology expertise and network in both countries,” said Dr. Kevin Pan, President of BSI/Yahong.

“This groundbreaking partnership will lead to the development of novel cancer medicines designed to treat common cancers in China,” said Dr. Li Yan, USCACA Managing Director. “This is a milestone for USCACA in terms of expanding its initiatives from scientific information exchange activities to real drug development programs. Our joint efforts will contribute to the improvement in clinical care of these largely unmet medical needs in China.” about Broad Sources/Jiangsu Yahong Pharmaceuticals Broad Sources, Inc. and Jiangsu Yahong Pharmaceuticals, Ltd. are affiliated companies. Broad Sources is in Chadds Ford, Pennsylvania, and Jiangsu Yahong in Taizhou China Medicine City, China. The companies’ vision is to rapidly and cost-effectively transform innovative discoveries into breakthrough therapies.   

about USCACA (www.uscaca.org)

USCACA is a not-for-profit organization with the mission to:

(a) Facilitates collaborations among Chinese American professionals in the field of cancer research, treatment and prevention; 

(b) Promotes knowledge and information exchange between the professionals in the United States and China;

(c) Provides educational information to serve cancer patients, their families, and the community.